Yes there is potential Competing Interest.
C. Saura have served as consultant, participated in advisory boards or received travel grants from AstraZeneca, Celgene, Daiichi Sankyo, Eisai, Roche, Genomic Health, MSD, Novartis, Pfizer, Philips Healthwork, Pierre Fabre, prIME Oncology, Puma Biotechnology, Synthon and Sanofi Aventis.
O. Córdoba was member of a scientific advisory board at GE and Ascires sistemas genómicos and GE, reports receiving commercial educational grants from Roche diagnostics, Neomedic and Takeda.
V. Peg have Received grants from Roche, played and advisory role for Roche, MSD, AstraZeneca and have received honoraria from Roche and Sysmex Spain.
P. Nuciforo has consulted for Bayer, Novartis, MSD, and Targos, and received compensation.
R. Dienstmann has declared advisory role for Roche, Boehringer Ingelheim, has received a speaker’s fee from Roche, Ipsen, Amgen, Servier, Sanofi, Merck Sharp & Dohme and Medscape, and research grants from Merck and Pierre Fabre.
J. Arribas has received research funds from Roche, Synthon, Menarini, and Molecular Partners and consultancy honoraria from Menarini.
J. Tabernero reports personal financial interest in form of scientific consultancy role for Array Biopharma, AstraZeneca, Avvinity, Bayer, Boehringer Ingelheim, Chugai, Daiichi Sankyo, F. Hoffmann-La Roche Ltd, Genentech Inc, HalioDX SAS, Hutchison MediPharma International, Ikena Oncology, IQVIA, Lilly, Menarini, Merck Serono, Merus, MSD, Mirati, Neophore, Novartis, Orion Biotechnology, Peptomyc, Pfizer, Pierre Fabre, Samsung Bioepis, Sanofi, Seattle Genetics, Servier, Taiho, Tessa Therapeutics and TheraMyc. And also, educational collaboration with Imedex, Medscape Education, MJH Life Sciences, PeerView Institute for Medical Education and Physicians Education Resource (PER).
A. Vivancos is a scientific advisory board member at Incyte, Novartis, Merck, Roche, Bristol-Meyers-Squibb, Guardant Health and Bayer, consultant at Sysmex, reports receiving preclinical research grants from Bristol-Meyers-Squibb, Novartis and Roche, and has received Intellectual Property royalties (Technology Transfer DX Fields) from Ferrer.
No potential conflicts of interest were disclosed by the other authors.